Cargando…
Intracranial Virotherapy for a Canine Hemangioma
Intracranial hemangiomas are rare neoplastic lesions in dogs that usually appear with life-threatening symptoms. The treatment of choice is tumor resection; however, complete resection is rarely achieved. The patient’s prognosis therefore usually worsens due to tumor progression, and adjuvant treatm...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9569716/ https://www.ncbi.nlm.nih.gov/pubmed/36232978 http://dx.doi.org/10.3390/ijms231911677 |
_version_ | 1784809923768483840 |
---|---|
author | Delgado-Bonet, Pablo Tomeo-Martín, Beatriz Davinia Delgado-Bonet, Blanca Sardón-Ruiz, David Torrado-Carvajal, Angel Mateo, Isidro Perisé-Barrios, Ana Judith |
author_facet | Delgado-Bonet, Pablo Tomeo-Martín, Beatriz Davinia Delgado-Bonet, Blanca Sardón-Ruiz, David Torrado-Carvajal, Angel Mateo, Isidro Perisé-Barrios, Ana Judith |
author_sort | Delgado-Bonet, Pablo |
collection | PubMed |
description | Intracranial hemangiomas are rare neoplastic lesions in dogs that usually appear with life-threatening symptoms. The treatment of choice is tumor resection; however, complete resection is rarely achieved. The patient’s prognosis therefore usually worsens due to tumor progression, and adjuvant treatments are required to control the disease. Oncolytic viruses are an innovative approach that lyses the tumor cells and induces immune responses. Here, we report the intratumoral inoculation of ICOCAV15 (an oncolytic adenovirus) in a canine intracranial hemangioma, as adjuvant treatment for incomplete tumor resection. The canine patient showed no side effects, and the tumor volume decreased over the 12 months after the treatment, as measured by magnetic resonance imaging using volumetric criteria. When progressive disease was detected at month 18, a new dose of ICOCAV15 was administered. The patient died 31.9 months after the first inoculation of the oncolytic adenovirus. Furthermore, tumor-infiltrated immune cells increased in number after the viral administrations, suggesting tumor microenvironment activation. The increased number of infiltrated immune cells, the long survival time and the absence of side effects suggest that ICOCAV15 could be a safe and effective treatment and should be further explored as a novel therapy for canine hemangiomas. |
format | Online Article Text |
id | pubmed-9569716 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-95697162022-10-17 Intracranial Virotherapy for a Canine Hemangioma Delgado-Bonet, Pablo Tomeo-Martín, Beatriz Davinia Delgado-Bonet, Blanca Sardón-Ruiz, David Torrado-Carvajal, Angel Mateo, Isidro Perisé-Barrios, Ana Judith Int J Mol Sci Case Report Intracranial hemangiomas are rare neoplastic lesions in dogs that usually appear with life-threatening symptoms. The treatment of choice is tumor resection; however, complete resection is rarely achieved. The patient’s prognosis therefore usually worsens due to tumor progression, and adjuvant treatments are required to control the disease. Oncolytic viruses are an innovative approach that lyses the tumor cells and induces immune responses. Here, we report the intratumoral inoculation of ICOCAV15 (an oncolytic adenovirus) in a canine intracranial hemangioma, as adjuvant treatment for incomplete tumor resection. The canine patient showed no side effects, and the tumor volume decreased over the 12 months after the treatment, as measured by magnetic resonance imaging using volumetric criteria. When progressive disease was detected at month 18, a new dose of ICOCAV15 was administered. The patient died 31.9 months after the first inoculation of the oncolytic adenovirus. Furthermore, tumor-infiltrated immune cells increased in number after the viral administrations, suggesting tumor microenvironment activation. The increased number of infiltrated immune cells, the long survival time and the absence of side effects suggest that ICOCAV15 could be a safe and effective treatment and should be further explored as a novel therapy for canine hemangiomas. MDPI 2022-10-02 /pmc/articles/PMC9569716/ /pubmed/36232978 http://dx.doi.org/10.3390/ijms231911677 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Case Report Delgado-Bonet, Pablo Tomeo-Martín, Beatriz Davinia Delgado-Bonet, Blanca Sardón-Ruiz, David Torrado-Carvajal, Angel Mateo, Isidro Perisé-Barrios, Ana Judith Intracranial Virotherapy for a Canine Hemangioma |
title | Intracranial Virotherapy for a Canine Hemangioma |
title_full | Intracranial Virotherapy for a Canine Hemangioma |
title_fullStr | Intracranial Virotherapy for a Canine Hemangioma |
title_full_unstemmed | Intracranial Virotherapy for a Canine Hemangioma |
title_short | Intracranial Virotherapy for a Canine Hemangioma |
title_sort | intracranial virotherapy for a canine hemangioma |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9569716/ https://www.ncbi.nlm.nih.gov/pubmed/36232978 http://dx.doi.org/10.3390/ijms231911677 |
work_keys_str_mv | AT delgadobonetpablo intracranialvirotherapyforacaninehemangioma AT tomeomartinbeatrizdavinia intracranialvirotherapyforacaninehemangioma AT delgadobonetblanca intracranialvirotherapyforacaninehemangioma AT sardonruizdavid intracranialvirotherapyforacaninehemangioma AT torradocarvajalangel intracranialvirotherapyforacaninehemangioma AT mateoisidro intracranialvirotherapyforacaninehemangioma AT perisebarriosanajudith intracranialvirotherapyforacaninehemangioma |